Prognostic impact of diffuse large B-cell lymphoma subgroups in patients undergoing autologous SCT.
A total of 53 patients aged 18-60 years with high-intermediate or high-risk diffuse large B-cell lymphoma (DLBCL) were evaluated to analyze the impact of the cell of origin. Of 53 patients, 16 underwent autologous SCT (ASCT) in first remission and the rest received conventional chemotherapy. Immunohistochemistry was evaluated in 47 cases: 17 were of germinal center (GC) origin and 30 were of non-GC origin. There was no survival difference between the two groups. Overall survival (OS) and disease-free survival (DFS) at 3 years were 93 and 83%, respectively, for the 14 patients who underwent ASCT. Their DFS was significantly better than that of patients who achieved CR but did not undergo ASCT. We conclude that ASCT is safe and improves the DFS of high-intermediate and high-risk DLBCL, regardless of the cell of origin. This observation should be confirmed in a larger study.
Department of Hematology, School of Medicine, São Paulo University, Dr Eneas de Carvalho Aguiar Avenue 155, Cerqueira Cesar, São Paulo, Brazil. abrahallack@uol.com.br
A E
AE
Hallack Neto
F L
FL
Dulley
S A
SA
Coelho Siqueira
L F
LF
Pracchia
M
M
Belesso
R
R
Saboya
D
D
Sturaro
J U
JU
Amigo-Filho
A
A
Mendrone Junior
D A F
DA
Chamone
J
J
Pereira
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007150:Immunohistochemistry; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000473:pathology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis; D012189:Retrospective Studies; D015996:Survival Rate; D014182:Transplantation, Autologous; D055815:Young Adult
D019253:Proto-Oncogene Proteins c-bcl-2